Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis.

AIMS Use of ticlopidine in coronary stenting is limited by delayed onset of action. We studied the effects of clopidogrel, a rapidly acting analog of ticlopidine alone, and in combination with aspirin, in inhibiting stent thrombosis. METHODS Unpolished nitinol stents were deployed in a porcine ex vivo arteriovenous shunt and exposed to flowing arterial blood at a shear rate of approximately 1500. s-1. Stent thrombus, platelet aggregation and bleeding times were measured at baseline and after treatment. RESULTS Intravenous clopidogrel produced a rapid (within 30 min) and dose-dependent inhibition of stent thrombosis, with 87% reduction at a dose of 10 mg.kg-1 (P < 0.001). Aspirin alone (10 mg.kg-1) was minimally effective (20% inhibition P > 0.05) in inhibiting stent thrombosis. Combined treatment with clopidogrel and aspirin produced 95-98% inhibition of stent thrombosis, even at low doses of clopidogrel (2.5-5.0 mg.kg-1) (P < 0.0001). At effective doses both clopidogrel and combined therapy produced significant prolongation of bleeding time (P < 0.05) and inhibition of platelet aggregation (P < 0.05). CONCLUSION Clopidogrel, either alone or combined with aspirin, may have a potential role in preventing stent thrombosis in high-risk clinical situations.

[1]  M. Humbert,et al.  Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[2]  N. Maalej,et al.  Increased shear stress overcomes the antithrombotic platelet inhibitory effect of aspirin in stenosed dog coronary arteries. , 1996, Circulation.

[3]  G. Roubin,et al.  Stratification of the risk of thrombosis after intracoronary stenting for threatened or acute closure complicating coronary balloon angioplasty: a Cook registry study. , 1995, American heart journal.

[4]  V. Fuster,et al.  Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene. , 1987, The Journal of laboratory and clinical medicine.

[5]  M. Bell,et al.  Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis. , 1996, Journal of the American College of Cardiology.

[6]  M. Hadamitzky,et al.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.

[7]  D. Bennett,et al.  Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty. , 1990, British heart journal.

[8]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.

[9]  W Rutsch,et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.

[10]  J. Herbert,et al.  Binding of [3H]-2-methylthio ADP to rat platelets--effect of clopidogrel and ticlopidine. , 1994, The Journal of pharmacology and experimental therapeutics.

[11]  G. Born,et al.  The aggregation of blood platelets , 1963, The Journal of physiology.

[12]  J. Maffrand,et al.  Combined ADP and Thromboxane A2 Antagonism Prevents Cyclic Flow Variations in Stenosed and Endothelium‐Injured Arteries in Nonhuman Primates , 1993, Circulation.

[13]  K. Schrör.  Antiplatelet drugs. A comparative review. , 1995, Drugs.

[14]  J. Herbert,et al.  Aprotinin reduces clopidogrel-induced prolongation of the bleeding time in the rat. , 1993, Thrombosis research.

[15]  H. Anderson,et al.  Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. , 1994, The American journal of physiology.

[16]  R. Erbel,et al.  Subacute thrombotic complications after intracoronary implantation of Palmaz-Schatz stents. , 1993, American heart journal.

[17]  G. Kieffer,et al.  Clopidogrel – a Platelet Inhibitor which Inhibits Thrombogenesis in Non-Anticoagulated Human Blood Independently of the Blood Flow Conditions , 1994, Thrombosis and Haemostasis.

[18]  Larry S. Dean,et al.  Intracoronary Stenting for Acute and Threatened Closure Complicating Percutaneous Transluminal Coronary Angioplasty , 1992, Circulation.

[19]  W Rutsch,et al.  Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. , 1996, Circulation.

[20]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[21]  J. Herbert,et al.  The Antiaggregating Activity of Clopidogrel Is due to a Metabolic Activation by the Hepatic Cytochrome P450-1A , 1994, Thrombosis and Haemostasis.

[22]  J. Douglas,et al.  Clinical and Angiographic Outcomes After Coronary Artery Stenting for Acute or Threatened Closure After Percutaneous Transluminal Coronary Angioplast Initial Results with a Balloon‐Expandable, Stainless Steel Design , 1993, Circulation.

[23]  M. Rosolowsky,et al.  ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. , 1992, Circulation research.

[24]  P. Serruys,et al.  Histology after stenting of human saphenous vein bypass grafts: observations from surgically excised grafts 3 to 320 days after stent implantation. , 1993, Journal of the American College of Cardiology.

[25]  A. Kapoor.  Interventional Cardiology , 1989, Springer New York.

[26]  E. Topol,et al.  Thrombosis of a flexible coil coronary stent: frequency, predictors and clinical outcome. , 1993, Journal of the American College of Cardiology.

[27]  J. Herbert,et al.  Potentiating Effect of Clopidogrel and SR 46349, a Novel 5-HT2 Antagonist, on Streptokinase-Induced Thrombolysis in the Rabbit , 1993, Thrombosis and Haemostasis.

[28]  David Schultz,et al.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.

[29]  S. Kaul,et al.  Inhibition of acute stent thrombosis under high-shear flow conditions by a nitric oxide donor, DMHD/NO. An ex vivo porcine arteriovenous shunt study. , 1996, Circulation.

[30]  S. Kaul,et al.  Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. , 1997, Circulation.

[31]  M. D. Freedman,et al.  Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[32]  W. Durante,et al.  Protein kinase C is activated in platelets subjected to pathological shear stress. , 1993, The Journal of biological chemistry.

[33]  J. Herbert,et al.  Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[34]  H. Goldsmith,et al.  Rheological Aspects of Thrombosis and Haemostasis: Basic Principles and Applications , 1986, Thrombosis and Haemostasis.

[35]  J. Carlson,et al.  Fatal Neutropenia and Thrombocytopenia Associated with Ticlopidine , 1994, The Annals of pharmacotherapy.